Yoshiya Tanaka, Tsutomu Takeuchi, Tatsuya Atsumi, Bernard G Combe, Daniel Aletaha, Toshihiko Kaise, Vijay Rajendran. Prevention of Radiographic Progression in Higher-Risk Patients with Rheumatoid Arthritis Using Filgotinib in Phase III Studies: Narrative Review of Post Hoc Analyses.Rheumatology and therapy. 2023, 10 (6): 1399-1415
Agner R Parra Sánchez, Ronald F van Vollenhoven, Eric F Morand, Ian N Bruce, Rangi Kandane-Rathnayake, Gudrun Weiss, Raj Tummala, Hussein Al-Mossawi, Alessandro Sorrentino. Targeting DORIS Remission and LLDAS in SLE: A Review.Rheumatology and therapy. 2023, 10 (6): 1459-1477
Philip J Mease, Alexis Ogdie, John Tesser, Natalie J Shiff, Iris Lin, Soumya D Chakravarty, Michael Kelleman, Rhiannon Dodge, Robert R McLean, Aaron Broadwell, Arthur Kavanaugh, Joseph F Merola. Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.Rheumatology and therapy. 2023, 10 (6): 1479-1501
Stephanie G Werner, Xenofon Baraliakos, Sabine Reckert, Martin Bohl-Bühler, Marie-Claude Laliberté, Tanya Girard, Katharina Jeromin, Nikola Baschuk, Björn Fritz, Louis Bessette, Axel J Hueber. Treatment with Upadacitinib in Active Psoriatic Arthritis: Efficacy and Safety Data of the First 192 Patients from the UPJOINT Study, a Multicentre, Observational Study in Clinical Practice.Rheumatology and therapy. 2023, 10 (6): 1503-1518
Leslie R Harrold, Patrick Zueger, W Benjamin Nowell, Taylor Blachley, Amy Schrader, Paul R Lakin, David Curtis, Laura Stradford, Shilpa Venkatachalam, Namita Tundia, Pankaj A Patel. A Real-World Effectiveness Study Using a Mobile Application to Evaluate Early Outcomes with Upadacitinib in Rheumatoid Arthritis.Rheumatology and therapy. 2023, 10 (6): 1519-1533
Alejandro Balsa, Siegfried Wassenberg, Yoshiya Tanaka, Anne Tournadre, Hans-Dieter Orzechowski, Vijay Rajendran, Udo Lendl, Pieter-Jan Stiers, Chris Watson, Roberto Caporali, James Galloway, Patrick Verschueren. Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis.Rheumatology and therapy. 2023, 10 (6): 1555-1574
Rieke Alten, Gerd R Burmester, Marco Matucci-Cerinic, Jean-Hugues Salmon, Andrew Östör, Khai Jing Ng, Jens Gerwien, Liliana Zaremba-Pechmann, Alan J M Brnabic, Bruno Fautrel. Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients.Rheumatology and therapy. 2023, 10 (6): 1575-1595
Xuan Huang, Qing Shu, Xuemei Luo, Weihong Ge, Han Xie, Yujie Zhou. Analysis of Factors Influencing Whole Blood Hydroxychloroquine Concentration in Patients with Systemic Lupus Erythematosus in China.Rheumatology and therapy. 2023, 10 (6): 1597-1607
Philip J Mease, Dafna D Gladman, Denis Poddubnyy, Soumya D Chakravarty, May Shawi, Alexa P Kollmeier, Xie L Xu, Stephen Xu, Atul Deodhar, Xenofon Baraliakos. Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study.Rheumatology and therapy. 2023, 10 (6): 1637-1653
Natalie Frede, Sonja Hiestand, Franziska Schauer, Dominique Endres, Ludger Tebartz van Elst, Markus Zeisbrich, Nils Craig-Mueller, Stephanie Finzel, Jens Thiel, Reinhard E Voll, Christoph Schempp, Nils Venhoff. Psoriasis and Psoriatic Arthritis Have a Major Impact on Quality of Life and Depressive Symptoms: A Cross-Sectional Study of 300 Patients.Rheumatology and therapy. 2023, 10 (6): 1655-1668
Laura C Cappelli, George Reed, Dimitrios A Pappas, Joel M Kremer. A Model to Predict Future Biologic or Targeted Synthetic DMARD Switch at a Subsequent Clinic Visit in Rheumatoid Arthritis.Rheumatology and therapy. 2023, 10 (6): 1669-1681